U.S. Food and Drug Administration Accepts for Priority Review the Biologics License Application for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma in Patients Who Have Received One or More Prior Therapies

By: via Benzinga
Bristol-Myers Squibb Company (NYSE: BMY) and AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.